Tachi is a Venture Partner on the Frazier Life Sciences team, focusing on company creation around innovative therapeutics.
Tachi originally joined Frazier Healthcare Partners as a Senior Advisor in 2006 and rejoined Frazier as a Venture Partner in 2015. Tachi is a member of the Life Sciences team and focuses on both creating companies as well as providing strategic guidance to existing portfolio companies.
Before rejoining Frazier, Tachi was Chief Medical and Scientific Officer at Takeda Pharmaceuticals in Tokyo, as well as a member of the Board of Directors. In this role, Tachi was responsible for all of Takeda’s research & development activities, with a budget of nearly $4 billion.
Prior to Takeda, Tachi was President of the Bill & Melinda Gates Foundation Global Health Program in Seattle, where he oversaw over $9 billion in grants for applying technologies to address major health challenges of the developing world. Before joining the Gates Foundation, Tachi was Chairman of Research and Development at GlaxoSmithKline and member of the board of directors. Earlier, Tachi was the Chief of the Division of Gastroenterology and the Chair of the Department of Internal Medicine at the University of Michigan in Ann Arbor.
In addition to his role at Frazier, Tachi serves as a member of the board of directors at the Clinton Health Access Initiative and a member of the Council of the National Academy of Medicine. He is also a Fellow of the Imperial College of Medicine, a Master of the American College of Physicians, a Fellow of the Royal College of Physicians, and a past-President of the American Gastroenterological Association and the Association of American Physicians.
Tachi received his M.D. from New York University School of Medicine and a B.A. in History from Stanford University. He has authored over 150 manuscripts in peer reviewed journals and is the editor of The Textbook of Gastroenterology. In recognition of his contributions to medicine and science he has been elected to membership in the Institute of Medicine of the National Academy of Sciences (US), the Academy of Medical Sciences (UK) and the National Academy of Medicine (Mexico). He has received an honorary appointment as Knight Commander of the Most Excellent Order of the British Empire (KBE) and been conferred the degree of D.Sci. honoris causa, from five universities. He has also been the recipient of numerous awards including the Distinguished Achievement Award in Gastrointestinal Physiology from the American Physiological Society, the Friedenwald Medal from the American Gastroenterological Association and the Watanabe Prize in Translational Research from Indiana University and Eli Lilly & Co.
Stanford University (B.A.)
New York University (M.D.)